Covance Elects Bradley T. Sheares to Company's Board of Directors
20 February 2009 - 8:01AM
PR Newswire (US)
PRINCETON, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Covance Inc.
(NYSE: CVD) today announced that it has elected Bradley T. Sheares,
Ph. D., to its Board of Directors. Dr. Sheares is former chief
executive officer and member of the Board of Directors of Reliant
Pharmaceuticals, Inc., a pharmaceutical company that marketed a
portfolio of branded cardiovascular medicines. Prior to joining
Reliant, he was president of the U.S. Human Health division of
Merck and Co., Inc., where he led commercial efforts in the United
States for the company's portfolio of prescription medicines for
the treatment of chronic and acute diseases. In addition to this
role, Dr. Sheares was a member of Merck's management committee,
which was responsible for formulating global business strategies,
managing operations and setting corporate policies. He joined Merck
in 1987 as research fellow in the Merck Research Laboratories, and
he held positions of increasing responsibility in Merck until his
departure in 2006. "We are very pleased to welcome Dr. Sheares to
our Board of Directors. His scientific background, academic
achievements and extensive experience in bringing new medicines to
the market will strengthen Covance's ability to provide innovative
drug development solutions to our clients, " said Joe Herring,
Covance chairman and CEO. "We look forward to leveraging Dr.
Sheares' outstanding record of leadership and management, as well
as his focus on recruiting top talent, to help our company sustain
its leadership position in the industry and continue to provide
value to our shareholders and employees." "Covance has been at the
forefront of creating innovative models of outsourcing," said Dr.
Sheares. "I am thrilled at the opportunity to be part of such an
accomplished group of individuals and to leverage my health care
experience in enhancing the company's ability to deliver
high-quality service and integrated solutions to its clients." Dr.
Sheares also serves on the Board of Directors of Honeywell
International, a diversified technology and manufacturing company,
and The Progressive Corporation, one of the nation's largest
insurance holding companies. In addition, he serves on the Board of
Trustees of Spelman College and is a member of the College of
Physicians of Philadelphia, the Abington Friends School Committee,
the Scientific Advisory Council for Montclair State University, and
the Executive Leadership Council. He is the former chair of the
Board of Directors of the National Pharmaceutical Council, which
focuses on broadly communicating the economic, clinical and
societal value of pharmaceuticals. Dr. Sheares graduated summa cum
laude with a bachelor's degree in chemistry from Fisk University
and earned his doctorate in biochemistry from Purdue University. He
completed his postdoctoral training as a Lucille P. Markey Scholar
and NIH Research Fellow at the Massachusetts Institute of
Technology. Covance, with headquarters in Princeton, New Jersey, is
one of the world's largest and most comprehensive drug development
services companies with annual revenues greater than $1.7 billion,
global operations in more than 20 countries, and more than 9,600
employees worldwide. Information on Covance's products and
services, recent press releases, and SEC filings can be obtained
through its website at http://www.covance.com/. DATASOURCE: Covance
Inc. CONTACT: Media, +1-609-419-2060, or Investors,
+1-609-452-4807, both of Covance Inc. Web Site:
http://www.covance.com/
Copyright